- GlaxoSmithKline's ViiV Healthcare joint venture with Pfizer said it had submitted a marketing authorisation application to the European Medicines Agency for its once-monthly injectable HIV-1 infection.

The application also included data for cabotegravir oral tablets, intended for use as oral lead-in therapy prior to the commencement of injectable therapy, the company said.

'If approved, this long-acting, injectable regimen of cabotegravir and rilpivirine has the potential to give people living with HIV one month between doses with similar safety and efficacy as today's standard of care - an oral, 3-drug regimen taken every day,' said Deborah Waterhouse, CEO of ViiV Healthcare.

At 9:34am: [LON:GSK] GlaxoSmithKline PLC share price was +18.5p at 1704.3p

Story provided by